Pular para o conteúdo principal
Ranking Invest

MDXG - MiMedx Group, Inc.

Segmento: HealthcareMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Análise Ranking Invest

Valuation estimado
$ 338.89 Mi
Valor de Mercado
$ 665.46 Mi
Sobrepreço (AV)+96.4%
IVR
0.51A companhia vale 0,51 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.17O valuation alternativo equivale a 17% do valor de mercado da companhia.
MLL
0.17O lucro líquido dos controladores em 16 trimestres equivale a 17% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 216.00 Mi

Dívida Líquida

-$ 118.63 Mi

L4T

$ 6.24 Mi

MM4T

-3.47%

Indicadores Básicos

ROE

2.89%

Índices de Previsibilidade

Receita Líquida

D0.12

Lucro

E2.00

Margem

F4.27

Índices de Tendência

Receita Líquida

C3.65

Lucro

D1.00

Margem

D-0.69

Índices de Endividamento

DIV/PAT

-0.55

DIV/L4T

-19.02

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.